Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A SERENITY At-Home pivotal, double-blind, placebo-controlled Phase 3 trial of BXCL501 for acute Treatment of agitation associated with bipolar disorders or schizophrenia in the home setting

Next Previous
X
Search
Trial Profile

A SERENITY At-Home pivotal, double-blind, placebo-controlled Phase 3 trial of BXCL501 for acute Treatment of agitation associated with bipolar disorders or schizophrenia in the home setting

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexmedetomidine (Primary)
  • Indications Agitation
  • Focus Adverse reactions; Registrational
  • Acronyms SERENITY At-Home
  • Sponsors BioXcel Therapeutics

    • Most Recent Events

    • 26 Sep 2024 According to a BioXcel Therapeutics media release BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation
    • 06 Sep 2024 New trial record
    • 05 Sep 2024 According to a BioXcel Therapeutics media release, company announced the initiation of patient enrollment in its SERENITY At-Home pivotal Phase 3 trial and the trial design summary presented in the media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top